



Product Information Sheet

Polyclonal Anti-SKP2

Catalogue No. PA1102

Lot No. 08F01

Ig type: rabbit IgG

Size: 100µg/vial

Specificity

Human, mouse, rat.


No cross reactivity with other proteins.

Recommended application


Western blot

Immunohistochemistry(P)

Immunocytochemistry



Lane 1 : Hela Whole Cell Lysate
Lane 2 : 6T-CEM Whole Cell Lysate



Immunogen

A synthetic peptide corresponding to a sequence at the N-terminal of human SKP2, different from the related rat and mouse sequence by three amino acids.

Purity

Immunogen affinity purified.

Application

Western blot

At 1µg/ml with the appropriate system to detect SKP2 in cells and tissues.

Immunohistochemistry(P)

At 1-2µg/ml to detect SKP2 in formalin fixed and paraffin embedded tissues.

Immunocytochemistry

At 1-2µg/ml to detect SKP2 in acetone fixed cell. Antigen retrieval by Pepsin and Trypsin is required.

Other applications have not been tested.

Optimal dilutions should be determined by end user.

Contents

To reorder contact us at:

Antagene, Inc.

Toll Free: 1(866)964-2589

email: Info@antageneinc.com

Each vial contains 5mg BSA, 0.9mg NaCl, 0.2mg Na₂HPO₄, 0.05mg Thimerosal, 0.05mg NaN₃.

Reconstitution

0.2ml of distilled water will yield a concentration of 500µg/ml.

FOR RESEARCH USE ONLY. NOT FOR DIAGNOSTIC AND CLINICAL USE.

Storage

and stored frozen at -20°C for longer time.

At -20°C for one year. After reconstitution, at 4°C for one month. It can also be aliquotted

BACKGROUND

The F box protein Skp2 (S-phase kinase-associated protein 2) is oncogenic, and its frequent amplification and overexpression correlate with the grade of malignancy of certain tumors. Skp2 controls p300-p53 signaling pathways in cancer cells, making it a potential molecular target for cancer therapy. This gene positively regulates the G(1)-S transition by controlling the stability of several G(1) regulators, such as the cell cycle inhibitor p27. This study provides evidence of a role for an F-box protein in oncogenesis and establishes SKP2 as a protooncogene causally involved in the pathogenesis of lymphomas.

REFERENCE

1. Kitagawa, M.; Lee, S. H.; McCormick, F. : Skp2 suppresses p53-dependent apoptosis by inhibiting p300. *Molec. Cell* 29: 217-231, 2008.
2. Latres, E.; Chiarle, R.; Schulman, B. A.; Pavletich, N. P.; Pellicer, A.; Inghirami, G.; Pagano, M. : Role of the F-box protein Skp2 in lymphomagenesis. *Proc. Nat. Acad. Sci.* 98: 2515-2520, 2001.